Income Taxes

9 Months Ended

Sep. 30, 2023

Income Tax Disclosure [Abstract]

Income Taxes

11. Income Taxes

The Company recorded $2.2 million of income tax expense in the third quarter of 2023 related to a change in estimate with respect to the tax treatment of the GSK License Agreement, which resulted in taxable income and the utilization of $240.9 million of US federal net operating losses and $6.1 million of US federal R&D tax credits in its 2022 US federal tax return.